Clovalyn Jeffrey-Mcgann
Family · Augusta, GANPI 1790247245
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,209 of the $18,724 with a category attached, or 65.2%. 38 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 31.8% of the total. Reporting peaked in 2024 at $8,956 and has fallen 75.1% since, to $2,227 in 2025. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 413 payments — averaging $45.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$6K
- Livanova USA, Inc.$4K
- UCB, Inc.$2K
- Neurelis, Inc.$2K
- SK Life Science, Inc.$1K
- Catalyst Pharmaceuticals, Inc.$574
- plus $3K from 32 others
What the payments were for
- Consulting fees$2,40313%
- Travel & lodging$4,11222%
- Food & beverage$12,20965%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$4,516
- VNS Therapy$3,194
- VALTOCO$592
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$276
- KOSELUGO$129
- Fintepla$125
- SUNOSI$125
- NEXLIZET$123
- NEXLETOL$123
- INGREZZA$118
- LOKELMA$111
- VNS - Sentiva$105
How this compares
$18,724 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 52 | $256,812 |
| XcopriCenobamate | 43 | $40,517 |
| NayzilamMidazolam | 31 | $19,390 |
| Oxcarbazepine | 48 | $4,706 |
| Lacosamide | 26 | $3,455 |
| Clobazam | 11 | $849 |
| Levetiracetam | 19 | $752 |
| Lamotrigine | 24 | $619 |
| Lorazepam | 23 | $323 |
| Gabapentin | 12 | $185 |
| Topiramate | 11 | $166 |
| Clonidine Hcl | 41 | $83 |
| Fluoxetine Hcl | 11 | $76 |
| Sertraline Hcl | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $1,158 | $40,51743 claims |
| UCB, Inc.Nayzilam | $2,378 | $19,39031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Augusta
- Stephanie JacobsonAugusta$24K
- Victoria BurtAugusta$15K
- Gloria DowneyAugusta$14K
- Joni SmithAugusta$14K
- Lindsey RobertsAugusta$13K
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.